In parallel, treatment of normal melanocytes with the mTORC1 inhibitor rapamycin down-modulated pS6, indicating the efficacy of its action (Fig. 2E) and it increased LC3 expression, as assessed by western blot (Fig. 2F) and immunofluorescence (Fig. 2G) analyses, proving that autophagy goes through mTORC1 pathway inhibition in vitiligo. The gene discussed is MAP1LC3A; the disease is vitiligo.